Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines

被引:14
作者
Daoud, Georges [1 ]
Monzer, Alissar [1 ]
Bahmad, Hisham [1 ]
Chamaa, Farah [1 ]
Hamdar, Layal [1 ]
Mouhieddine, Tarek H. [1 ]
Shayya, Sami [1 ]
Eid, Assaad [1 ]
Kobeissy, Firas [2 ]
Liu, Yen-Nien [3 ]
Abou-Kheir, Wassim [1 ]
机构
[1] Amer Univ Beirut, Dept Anat Cell Biol & Physiol Sci, Fac Med, Beirut, Lebanon
[2] Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon
[3] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan
关键词
prostate cancer; castration-resistant prostate cancer; cancer stem cells; Pten; TP53; OXIDATIVE STRESS; EXPRESSION; TRANSITION; MECHANISMS; DOCETAXEL; GROWTH; BETA;
D O I
10.18632/oncotarget.8436
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cell lines representing the progression of prostate cancer (PC) from an androgen-dependent to an androgen-independent state are scarce. In this study, we used previously characterized prostate luminal epithelial cell line (Plum), under androgen influence, to establish cellular models of PC progression. Cells derived from orthotopic tumors have been isolated to develop an androgen-dependent (PLum-AD) versus an androgen-independent (PLum-AI) model. Upon immunofluorescent, qRT-PCR and Western blot analyses, PLum-AD cells mostly expressed prostate epithelial markers while PLum-AI cells expressed mesenchymal cell markers. Interestingly, both cell lines maintained a population of stem/progenitor cells. Furthermore, our data suggest that both cell lines are tumorigenic; PLum-AD resulted in an adenocarcinoma whereas PLum-AI resulted in a sarcomatoid carcinoma when transplanted subcutaneously in NOD-SCID mice. Finally, gene expression profiles showed enrichment in functions involved in cell migration, apoptosis, as well as neoplasm invasiveness and metastasis in PLum-AI cells. In conclusion, these data suggest that the newly isolated cell lines represent a new in vitro model of androgen-dependent and -independent PC.
引用
收藏
页码:28961 / 28975
页数:15
相关论文
共 37 条
[1]   Molecular genetics of prostate cancer [J].
Abate-Shen, C ;
Shen, MM .
GENES & DEVELOPMENT, 2000, 14 (19) :2410-2434
[2]   Self-Renewing Pten-/-TP53-/- Protospheres Produce Metastatic Adenocarcinoma Cell Lines with Multipotent Progenitor Activity [J].
Abou-Kheir, Wassim ;
Hynes, Paul G. ;
Martin, Philip ;
Yin, Juan Juan ;
Liu, Yen-Nien ;
Seng, Victoria ;
Lake, Ross ;
Spurrier, Joshua ;
Kelly, Kathleen .
PLOS ONE, 2011, 6 (10)
[3]   Characterizing the Contribution of Stem/Progenitor Cells to Tumorigenesis in the Pten-/- TP53-/- Prostate Cancer Model [J].
Abou-Kheir, Wassim G. ;
Hynes, Paul G. ;
Martin, Philip L. ;
Pierce, Rachel ;
Kelly, Kathleen .
STEM CELLS, 2010, 28 (12) :2129-2140
[4]   Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment [J].
Aggarwal, Rahul ;
Harris, Anna ;
Formaker, Carl ;
Small, Eric J. ;
Molina, Arturo ;
Griffin, Thomas W. ;
Ryan, Charles J. .
CLINICAL GENITOURINARY CANCER, 2014, 12 (05) :E167-E172
[5]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[6]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[7]   WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics [J].
Bisson, Isabelle ;
Prowse, David M. .
CELL RESEARCH, 2009, 19 (06) :683-697
[8]   Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases [J].
Chao, Yvonne ;
Wu, Qian ;
Acquafondata, Marie ;
Dhir, Rajiv ;
Wells, Alan .
CANCER MICROENVIRONMENT, 2012, 5 (01) :19-28
[9]  
Chaturvedi Shruti, 2014, J Carcinog, V13, P5, DOI 10.4103/1477-3163.128185
[10]   Development of prostate cancer treatment: The good news [J].
Denmeade, SR ;
Isaacs, JT .
PROSTATE, 2004, 58 (03) :211-224